Post #98: Bigger and better biotech

2020 has been the year when we have all used with unfortunate regularity terms such as antibodies, asymptomatic, placebo, vaccine and more.

Post #98: Bigger and better biotech

2020 has been the year when we have all used with unfortunate regularity terms such as antibodies, asymptomatic, placebo, vaccine and more. Although the tragic cost of COVID-19 continues to be counted, the virus has at least succeeded in shining a huge spotlight on the biotech industry. With growing investor and public interest in the sector, we were lucky enough to hear the views of four experts within the field (three of whom had Doctorates) at a webinar yesterday.

Similar to how the pandemic has accelerated digital adoption in areas such as online retail and payment, one of yesterday’s speakers (Dr Barbara Domayne-Hayman, an entrepreneur who began her career at Astra Zeneca) described how recent collaboration across the biotech industry had “done in ten months what normally takes ten years.” Interestingly, while big pharma (not just Astra, but also, say, Pfizer) have scaled up vaccination projects, much of the grassroots innovation with regard to understanding and solving COVID-19 occurred at an academic and/or biotech level. The legacy of such a partnership approach should be enduring when it comes to finding cures for other viruses, per the consensus among the speakers.

When the panellists were asked about what would be ‘the next big thing’ for the industry, two clear themes emerged: the digitalisation of the healthcare industry and innovation with regard to dementia.With regard to the former, it was described as “an unstoppable movement” (by Dr Andy Richards CBE, a biotech entrepreneur and investor). Look out for developments across a broad spectrum which encompasses healthcare monitoring, rehabilitation and telemedicine. Turning to dementia and diseases more broadly affecting the brain, this will matter increasingly, particularly as populations age. Separately, we were pleased to note that Novo Nordisk announced yesterday that one of its drugs had entered phase three trials for Alzheimer’s disease.

One final consideration, or perhaps the $64,000 question, is what should investors look for if they want involvement in the sector. Spoiler alert: there is no single answer, but the panellists asserted that quality management was key – we concur. With biotech specifically, it is integral to understand exactly what problems companies are trying to solve and whether they are even worth solving in the first place (in terms of cost-benefit). Our approach to the sector also involves trying to think laterally, looking to businesses involved in the value chain, particularly in terms of life sciences tools and equipment.

The above does not constitute investment advice and is the sole opinion of the author at the time of publication. Heptagon Capital is an investor in Novo Nordisk. The author of this piece has no personal direct investment in the business. Past performance is no guide to future performance and the value of investments and income from them can fall as well as rise.​​​​​​​

Alex Gunz, Fund Manager


The document is provided for information purposes only and does not constitute investment advice or any recommendation to buy, or sell or otherwise transact in any investments. The document is not intended to be construed as investment research. The contents of this document are based upon sources of information which Heptagon Capital believes to be reliable. However, except to the extent required by applicable law or regulations, no guarantee, warranty or representation (express or implied) is given as to the accuracy or completeness of this document or its contents and, Heptagon Capital, its affiliate companies and its members, officers, employees, agents and advisors do not accept any liability or responsibility in respect of the information or any views expressed herein. Opinions expressed whether in general or in both on the performance of individual investments and in a wider economic context represent the views of the contributor at the time of preparation. Where this document provides forward-looking statements which are based on relevant reports, current opinions, expectations and projections, actual results could differ materially from those anticipated in such statements. All opinions and estimates included in the document are subject to change without notice and Heptagon Capital is under no obligation to update or revise information contained in the document. Furthermore, Heptagon Capital disclaims any liability for any loss, damage, costs or expenses (including direct, indirect, special and consequential) howsoever arising which any person may suffer or incur as a result of viewing or utilising any information included in this document. 

The document is protected by copyright. The use of any trademarks and logos displayed in the document without Heptagon Capital's prior written consent is strictly prohibited. Information in the document must not be published or redistributed without Heptagon Capital's prior written consent. 

Heptagon Capital LLP, 63 Brook Street, Mayfair, London W1K 4HS
tel +44 20 7070 1800
fax +44 20 7070 1881
email [email protected] 

Partnership No: OC307355 Registered in England and Wales Authorised & Regulated by the Financial Conduct Authority 

Related Insights

Featured Insights
Featured Insights23 September 2021

Season 3, Post 36: Houses of the future

We’ve all spent more time than we might have anticipated in our homes over the past year. Even with many countries now reopening, it seems likely that the future will comprise more of a balance between home and the office. Our houses will almost certainly therefore (need to) become smarter. For one perspective, go to […]

Learn more
Future Trends Blog
Future Trends Blog15 September 2021

Season 3, Post 35: Benjamin Franklin was right…

Perhaps the most famous observation made by Benjamin Franklin, one of America’s Founding Fathers, is that “in this world nothing can be said to be certain, except death and taxes” Accept this maxim and it is only a step to recognising that arguably the biggest problem – or future trend – that the world faces is how to […]

Learn more
Featured Insights
Featured Insights09 September 2021

Season 3, Post 34: The future is meatless

If everyone in the UK were to eat just one more plant-based meal a week than they currently do, then this would be equivalent to taking 16m cars off the road, thereby reducing the country’s carbon emissions by over 8%. That’s a pretty good incentive for cutting down on meat consumption. An equally compelling one […]

Learn more

Get The Updates

Separated they live in Bookmarks right at the coast of the famous Semantics, large language ocean Separated they live in Bookmarks right


Sign up to our monthly email newsletter for the latest fund updates, webcasts and insights.